Clik here to view.
Isotechnika partner files drug applications
Isotechnika Pharma’s (TSX:ISA) partner, Lux Biosciences, has filed a new drug application with the FDA and a market authorization application with the European Medicines Agency for voclosporin, under...
View ArticleClik here to view.
Isotechnika amends deal with Paladin Labs
Isotechnika Pharma’s (TSX: ISA) wholly owned subsidiary, Isotechnika Labs, has amended its agreement with Paladin Labs (TSX:PLB) on the remaining stake in the revenue stream from the Isodiagnostika...
View ArticleClik here to view.
EMA accepts Isotechnika-Lux filing for eye drug
The European Medicines Agency has accepted a marketing application filed by Isotechnika Pharma’s (TSX:ISA) partner, Lux Biosciences, for voclosporin to treat non-infectious uveitis involving the...
View ArticleClik here to view.
Isotechnika has a powerhouse franchise in voclosporin
Dr. Robert Foster still longs to make Isotechnika’s (TSX: ISA) lead drug, voclosporin, the standard of care in the field of preventing organ rejection in transplantation surgery. This may seem somewhat...
View ArticleClik here to view.
FDA cancels meeting but review of Isotechnika’s voclosporin continues
The FDA has cancelled a June 28 dermatology and ophthalmology drugs advisory committee review of a new drug application by Isotechnika Pharma’s (TSX:ISA) partner Lux Biosciences for their voclosporin...
View ArticleClik here to view.
Paladin, Isotechnika submit Voclera in Canada
Paladin Labs (TSX:PLB) and Isotechnika (TSX:ISA) have submitted Voclera, a treatment for moderate to severe psoriasis, for marketing approval in Canada. Voclera was discovered by Isotechnika and has...
View ArticleClik here to view.
Isotechnika releases shareholder letter
In a letter to shareholders issued today, Isotechnika Pharma (TSX:ISA) CEO Dr. Robert Foster explains the company’s decision to move its voclosporin drug into Phase 3 clinical trials for the prevention...
View ArticleClik here to view.
Donald Wyatt joins Isotechnika board
Donald Wyatt, the founder of consultancy The Wyatt Group, has been appointed a director of Isotechnika Pharma (TSX:ISA), serving as a representative of 3SBio (NASDAQ:SSRX), a Chinese biotech company....
View ArticleClik here to view.
Isotechnika in license pact with Vifor Pharma
Isotechnika Pharma (TSX:ISA) has signed a global development and commercialization license agreement with Vifor Pharma, a member of the Swiss Galenica Group, for its lead drug, voclosporin, for the...
View ArticleClik here to view.
FDA clears Isotechnika for Phase 3 voclosporin trial
Isotechnika Pharma (TSX:ISA) has received permission from the FDA to commence the first of two planned Phase 3 kidney transplant trials for its lead product candidate, voclosporin, under a special...
View Article
